Zydus Lifesciences has announced a major strategic partnership with Germany-based Formycon AG to develop and commercialize FYB206, a biosimilar version of the blockbuster immunotherapy Keytruda® (pembrolizumab), for the United States and Canadian markets. The collaboration marks Zydus’ entry into the North American biosimilars space and represents a significant move to expand access to affordable oncology treatments in regions where cancer immunotherapies remain costly for many patients.
Under the terms of the agreement, Zydus’ wholly owned subsidiary, Zydus Lifesciences Global FZE in the United Arab Emirates, will hold exclusive commercialization rights for FYB206 in the U.S. and Canada. Formycon will lead development, regulatory filings, manufacturing, and supply. A Biologics License Application (BLA) for FYB206 is expected to be submitted to the U.S. Food and Drug Administration in the near future, positioning the companies to compete in one of the world’s most lucrative immuno-oncology markets once biosimilar versions of Keytruda begin to enter.
Keytruda, a PD-1 checkpoint inhibitor used across multiple cancer types, generated more than USD 25 billion in annual sales globally and is set to face biosimilar competition later this decade. Biosimilars of the therapy are widely anticipated due to the potential for dramatically lowering costs and expanding access to advanced cancer care. With FYB206, Zydus and Formycon aim to be among the early players entering this competitive landscape.
Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences, emphasized the significance of the partnership for the company’s global ambitions. “We are happy to collaborate with Formycon to develop and commercialize a biosimilar of Keytruda across the U.S. and Canada. This venture marks Zydus’ entry into the North American biosimilar market, debuting with an immunotherapy product,” he said. Patel added that the collaboration aligns with the company’s recent proposed acquisition of Agenus Inc.’s manufacturing facilities in California—an expansion expected to strengthen Zydus’ biologics capabilities and support future large-scale production.
“This partnership strengthens our commitment to delivering affordable oncology care, combining expertise and resources to maximize patient access,” Patel said, noting the company’s broader mission to improve global healthcare equity.
Formycon CEO Dr. Stefan Glombitza highlighted the scientific and regulatory strengths that underpin FYB206. “FYB206, a biosimilar of Keytruda, demonstrates Formycon’s advanced expertise in developing biosimilar medicines for highly regulated countries,” he said. “Partnering with Zydus, an organization recognized for its regulatory proficiency and commercial presence, enables us to deliver this important therapeutic option to patients.”
The agreement gives both companies a strong foothold in the growing biosimilars market, which continues to expand as major biologic therapies lose exclusivity. With rising cancer incidence and increasing pressure to reduce healthcare costs, demand for high-quality, lower-cost alternatives to branded immunotherapies is projected to surge.
As regulatory filings move forward and manufacturing plans take shape, the partnership positions Zydus and Formycon to play a meaningful role in broadening access to immuno-oncology innovations across North America—potentially reshaping treatment affordability for patients who rely on life-extending cancer therapies.